Lyon wrote:
Hi Lew, The President of Opexa has already stated that Tovaxin would cost about the same as the crabs but due to the time confines when shipping the blood and the vaccine they won't be able to make one huge factory to supply it for the world, as you could with a drug. Tovaxin is going to require multiple regional labs, all with the same quality control standards.
It seems that would take a while to set up and it seems that would be expensive.Bob
That sounds logical--and as though they're ready to roll as soon as they get the cash infusion they'll need to launch Phase III.
I keep swinging back and forth when I try to guess about the cost. Zapping our own gunk shouldn't, to my of thinking, be as costly as developing a big whoppin' piece of chemistry--and other goodies to manage side effects of said heavy-duty drug.
Then again, Opexa has a lot of research outlay to recover. Heaven knows what sorts of tabs each of us lab rats is running up each month. So it's a guessing game.
I'll never forget the price-gouging that went on when they re-released Tysabri (I'd been 24 hours from first infusion when Ty got yanked off the market--can we say "temper tantrum"?).
Whatever happens, my curiosity is killing me.
